Union Health Minister Mansukh Mandaviya announced on Tuesday that India has approved two new COVID-19 vaccines namely Covovax and Corbevax. In addition to this, an anti-viral drug, Molnupiravir, has also been approved for restricted use in an emergency situation.&nbsp;<o:p></o:p>

"Further strengthening the fight against Covid-19, CDSCO, health ministry has given 3 approvals in a single day for CORBEVAX vaccine, COVOVAX vaccine, anti-viral drug Molnupiravir for restricted use in an emergency situation," Mansukh Mandaviya reported through Twitter.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/live-india-covid-omicron-vaccine-travel-updates-440325" hreflang="en">LIVE Omicron Variant Updates: India reports 6,358 cases; Omicron cases now 653</a>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Congratulations India 🇮🇳 
 
Further strengthening the fight against COVID-19, CDSCO, <a href="https://twitter.com/MoHFW_INDIA?ref_src=twsrc%5Etfw">@MoHFW_INDIA</a> has given 3 approvals in a single day for: 
 
- CORBEVAX vaccine 
- COVOVAX vaccine 
- Anti-viral drug Molnupiravir 
 
For restricted use in emergency situation. (1/5)
— Dr Mansukh Mandaviya (@mansukhmandviya) <a href="https://twitter.com/mansukhmandviya/status/1475699946544570372?ref_src=twsrc%5Etfw">December 28, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

CORBEVAX is India’s first indigenously developed RBD protein sub-unit vaccine against the deadly coronavirus. This is being made by Hyderabad-based firm Biological-E.<o:p></o:p>

<o:p></o:p>

COVOVAX, manufactured by Pune-based firm Serum Institute of India (SII), is a nanoparticle vaccine against COVID-19.

Molnupiravir is an antiviral drug that is being developed by nearly 13 companies in India. This can be used to treat adult patients of Covid who, the doctors believe, have a heightened risk of "progression of the disease". The antiviral drug will not be used for Covid patients under the age of 18, for now, as per local media reports.

<a href="https://www.wionews.com/videos/india-approves-2-more-covid-19-vaccines-and-an-anti-covid-pill-molnupiravir-440613">WATCH |</a>

<o:p></o:p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/india-approves-2-more-covid-19-vaccines-and-an-anti-covid-pill-molnupiravir-440613/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

In addition to this, it is also believed that this antiviral drug will not be used for more than five consecutive days, as of now.<o:p></o:p>

With these new approvals, the number of approved Covid vaccines has increased to eight. Till now, Covishield, Covaxin, Sputnik V, Moderna, Johnson and Johnson and ZyCoV-D had approvals India.<o:p></o:p>

This news comes a little after Indian Prime Minister made a surprise announcement on Christmas Day through a national TV telecast about Covid vaccination for children and 'precaution dose' for frontline workers and those above 60 years of age and with comorbidities.<o:p></o:p>

Union Health Minister Mansukh Mandaviya announced on Tuesday that India has approved two new COVID-19 vaccines namely Covovax and Corbevax. In addition to this, an anti-viral drug, Molnupiravir, has also been approved for restricted use in an emergency situation.

Union Health Minister Mansukh Mandaviya announced on Tuesday that India has approved two new COVID-19 vaccines namely Covovax and Corbevax. In addition to this, an anti-viral drug, Molnupiravir, has also been approved for restricted use in an emergency situation. "Further strengthening the fight against Covid-19, CDSCO, health ministry has given 3 approvals in a single day for CORBEVAX vaccine, COVOVAX vaccine, anti-viral drug Molnupiravir for restricted use in an emergency situation," Mansukh Mandaviya reported through Twitter. Also read | LIVE Omicron Variant Updates: India reports 6,358 cases; Omicron cases now 653 Congratulations India 🇮🇳 Further strengthening the fight against COVID-19, CDSCO, @MoHFW_INDIA has given 3 approvals in a single day for: - CORBEVAX vaccine - COVOVAX vaccine - Anti-viral drug Molnupiravir For restricted use in emergency situation. (1/5) — Dr Mansukh Mandaviya (@mansukhmandviya) December 28, 2021 × CORBEVAX is India’s first indigenously developed RBD protein sub-unit vaccine against the deadly coronavirus. This is being made by Hyderabad-based firm Biological-E. COVOVAX, manufactured by Pune-based firm Serum Institute of India (SII), is a nanoparticle vaccine against COVID-19. Molnupiravir is an antiviral drug that is being developed by nearly 13 companies in India. This can be used to treat adult patients of Covid who, the doctors believe, have a heightened risk of "progression of the disease". The antiviral drug will not be used for Covid patients under the age of 18, for now, as per local media reports. WATCH | In addition to this, it is also believed that this antiviral drug will not be used for more than five consecutive days, as of now. With these new approvals, the number of approved Covid vaccines has increased to eight. Till now, Covishield, Covaxin, Sputnik V, Moderna, Johnson and Johnson and ZyCoV-D had approvals India. This news comes a little after Indian Prime Minister made a surprise announcement on Christmas Day through a national TV telecast about Covid vaccination for children and 'precaution dose' for frontline workers and those above 60 years of age and with comorbidities.

'It's a hat-trick!': India approves 2 new Covid vaccines and 1 antiviral drug in a day

The Drugs Controller General of India (DCGI) has approved Biological E for two clinical trials of its COVID-19 vaccine candidate Corbevax, according to an official notification from the ministry of science and technology on September 3.

After a subject expert committee reviewed Phase 1 and 2 clinical trial data, the Hyderabad-based pharmaceutical company gained approval for a Phase 3 comparative safety and immunogenicity trial in adults.

The DBT and BIRAC, according to the ministry, have sponsored Corbevax, an RBD protein subunit vaccine, through preclinical to Phase 3 clinical trials.&nbsp;

Biological E's vaccine candidate has also received funding backing from the National Biopharma Mission, BIRAC, under the COVID-19 Research Consortia.

"This vaccine candidate has received financial support under COVID-19 Research Consortia through the National Biopharma Mission, BIRAC, in addition to getting financial help under Mission COVID Suraksha," according to the official statement.&nbsp;

Six vaccinations have been approved for use in the country, but only 11.28 percent of the population has been properly vaccinated, according to data from Johns Hopkins.

The Covid-19 shots for adults, created by Bharat Biotech and Zydus Cadila, are among them.

Late in August, India approved Cadila's Covid-19 vaccine, the world's first DNA coronavirus vaccine, for emergency use in children aged 12 and up.

A late-stage trial of Biological E's coronavirus vaccination in adults is currently underway.

(With inputs from agencies)

The Drugs Controller General of India (DCGI) has approved Biological E for two clinical trials of its COVID-19 vaccine candidate Corbevax, according to an official notification from the ministry of science and technology on September 3.

The Drugs Controller General of India (DCGI) has approved Biological E for two clinical trials of its COVID-19 vaccine candidate Corbevax, according to an official notification from the ministry of science and technology on September 3. After a subject expert committee reviewed Phase 1 and 2 clinical trial data, the Hyderabad-based pharmaceutical company gained approval for a Phase 3 comparative safety and immunogenicity trial in adults. The DBT and BIRAC, according to the ministry, have sponsored Corbevax, an RBD protein subunit vaccine, through preclinical to Phase 3 clinical trials. Biological E's vaccine candidate has also received funding backing from the National Biopharma Mission, BIRAC, under the COVID-19 Research Consortia. "This vaccine candidate has received financial support under COVID-19 Research Consortia through the National Biopharma Mission, BIRAC, in addition to getting financial help under Mission COVID Suraksha," according to the official statement. Six vaccinations have been approved for use in the country, but only 11.28 percent of the population has been properly vaccinated, according to data from Johns Hopkins. The Covid-19 shots for adults, created by Bharat Biotech and Zydus Cadila, are among them. Late in August, India approved Cadila's Covid-19 vaccine, the world's first DNA coronavirus vaccine, for emergency use in children aged 12 and up. A late-stage trial of Biological E's coronavirus vaccination in adults is currently underway. (With inputs from agencies)

Government gives Biological E nod to study its Covid vaccine Corbevax in children, teens

covid-vaccine-corbevax

Covid Vaccine Corbevax, News on Covid Vaccine Corbevax, stories on Covid Vaccine Corbevax, articles on Covid Vaccine Corbevax, Covid Vaccine Corbevax stories at Wion, Covid Vaccine Corbevax news, Covid Vaccine Corbevax latest news

covid vaccine-corbevax

'It's a hat-trick!': India approves 2 new Covid vaccines and 1 antiviral drug in a day

Government gives Biological E nod to study its Covid vaccine Corbevax in children, teens